Pulmatrix, Inc.
PULMPulmatrix is a biopharmaceutical company specializing in the development of novel inhaled therapeutic products for central nervous system disorders and respiratory diseases.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
Profile
Pulmatrix is a biopharmaceutical company specializing in the development of novel inhaled therapeutic products for central nervous system disorders and respiratory diseases. The company utilizes its proprietary iSPERSE dry powder delivery platform to engineer small, dense particles that improve drug delivery to the lungs while optimizing pharmacokinetics and reducing systemic side effects. Pulmatrix is currently undergoing a strategic transition involving a planned merger with Cullgen Inc. and the monetization of its existing clinical assets.
Pulmatrix holds a specialized position in pulmonary drug delivery with its iSPERSE platform, though it is currently transitioning from an active developer to a strategic asset monetizer.
Questions, answered.
- What is Pulmatrix, Inc.'s market cap?
- Pulmatrix, Inc. (PULM) has a market capitalization of $6.3M and trades on NASDAQ.
- Who are Pulmatrix, Inc.'s competitors?
- Pulmatrix, Inc.'s key competitors include Insmed, Amneal Pharmaceuticals, Inc., Philip Morris International, Inc., and others. These companies compete in similar markets and product categories.
- Who does Pulmatrix, Inc. partner with?
- Pulmatrix, Inc.'s notable partners include Cullgen Inc., Cipla, MannKind Corporation, and others.
- What subsidiaries does Pulmatrix, Inc. have?
- Pulmatrix, Inc.'s subsidiaries include Pulmatrix Operating Company, Inc., PCL Merger Sub, Inc..
- Where is Pulmatrix, Inc. headquartered?
- Pulmatrix, Inc. is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 2014.